SectorPharmaceutical
Established Date24/08/2012
Listing Date13/10/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees2
Fiscal Year Ends31/12
Security TypeCommon stock
Office address3710—33rd Street NW, Calgary, Alberta, T2L 2M1, Canada
Business
IntroductionXORTX Therapeutics Inc., was incorporated under the laws of Alberta, Canada on August 24, 2012 under the name ReVasCor Inc. On January 10, 2018, the company name was changed to "XORTX Therapeutics Inc.". The Company is a clinical-stage biotechnology company focused on identifying, developing and commercializing therapies for progressive kidney disease regulated by abnormal purine and uric acid metabolism in renal indications including ADPKD, AKI caused by coronavirus COVID 19 infection and T2DN.
